XL 413

Drug Profile

XL 413

Alternative Names: BMS-863233; EXEL 5413; XL-413

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CDC7 protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Haematological malignancies; Solid tumours

Most Recent Events

  • 11 Aug 2010 Bristol-Myers Squibb and Exelixis terminate phase I/II trial [NCT00838890] in refractory Haematological malignancies in USA
  • 11 Aug 2010 Bristol-Myers Squibb and Exelixis terminate phase I/II trial [NCT00886782] in late-stage and/or metastatic Solid tumours in USA, Canada and France
  • 27 Nov 2008 Exelixis and Bristol-Myers Squibb select to co-develop XL 413 in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top